Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) – By Type, Drug, Stages, Route of Administration, Age Group End User and Region.

Global Age Related Macular Degeneration (AMD) Market was valued US$ XX Bn in 2018 and is expected to reach XX Bn by 2026, at a CAGR of XX % during a forecast period. Age-related macular degeneration is the prominent cause of severe, irreversible vision loss in people over age 60. It occurs when the small central portion of the retina deteriorates. Global Age Related Macular Degeneration (AMD) Market To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Growing population across the globe and the demography reflecting the predominance of the older population, the global affliction of AMD continues to increase at an unprecedented rate. The development of gene therapy for AMD, the growth in the geriatric population, and awareness concerning the AMD are some major factors behind the growth of the global age-related macular degeneration (AMD) market. Additionally, High prevalence of AMD is one of the key drivers in the global age-related macular degeneration (AMD) market. Factors like aging, smoking, high cholesterol, and high blood pressure are causing the prevalence of AMD. On the other hand, high cost of the treatment, off –label usage and strict regulatory policies are some of the factors, which are expected to limit the growth in the global age-related macular degeneration (AMD) market. The risk of the occurring the AMD is directly proportional to the age. With the number of people aged above 60 years, the prevalence of AMD is also growing. In 2017, there were, about XX Mn people in the age group 60 years over across the globe, and the number is projected to grow XX Bn during the forecast period. So, the geriatric population is growing faster than younger age groups. Wet Age-related Macular Degeneration (WAMD) treatment is expected to contribute significant share in the Global Age-Related Macular Degeneration (AMD), market. For wet AMD treatment, the anti-vascular endothelial growth factor is commonly used, which helps to pause or delay the progression of visual loss. By delaying the action of VEGF chemical, it aids to prevent the condition from progressing and partially reverse it. Anti-VEGF medicines include Eylea, Lucentis and Avastin. Region-wise, The Asia Pacific region is projected to be leading region in the Global age-related macular degeneration (AMD) market. The market in the Asia Pacific region is set to experience favourable growth, which is driven by factors like the elderly population & rising health care expenditure. An increase in the obese population and economic development are also expected to boost the growth in the age-related macular degeneration (AMD) market. A rise in the number of pipeline drugs for age-related macular degeneration is facilitating the industry key players to sustain in the global age-related macular degeneration market. Additionally, fast track drug designations and regulator government policies like tax benefits are some of the prominent factors aiding the new key players to enter in the age-related macular degeneration market. For instance, Fovista, which is a product of Ophthotech received fast track designation by U.S. FDA and launched in 2018. The objective of the report is to present comprehensive analysis of global age related macular degeneration (AMD) market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global age related macular degeneration (AMD) market dynamics, structure by analysing the market segments, and project the global age related macular degeneration (AMD) market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the global age related macular degeneration (AMD) market make the report investor’s guide.

The Scope of the Report for Global Age Related Macular Degeneration (AMD) Market: Inquire before buying

Global Age Related Macular Degeneration (AMD) Market, By Type

• Dry Age-related Macular Degeneration (DAMD) • Wet Age-related Macular Degeneration (WAMD)

Global Age Related Macular Degeneration (AMD) Market, By Drug

• Lucentis • Eylea • Avastin • Others

Global Age Related Macular Degeneration (AMD) Market, By Stages

• Intermediate Stage Age Related Macular Degeneration • Early-Stage Age Related Macular Degeneration • Late Stage Age Related Macular Degeneration

Global Age Related Macular Degeneration (AMD) Market, By Route of Administration

• Intravenous • Intravitreal

Global Age Related Macular Degeneration (AMD) Market, By Age Group

• Above 75 Year • Above 60 Year • Above 40 Year

Global Age Related Macular Degeneration (AMD) Market, By End User

• Hospitals & Clinics • Dignostic Centers • Academic Research Institutes

Global Age Related Macular Degeneration (AMD) Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in Global Age Related Macular Degeneration (AMD) Market

• Kubota Pharmaceutical Holdings Co. Ltd. • Alimera Sciences Inc. • Adverum Biotechnologies Inc. • Gilead Sciences Inc. • Apellis Pharmeceuticals Inc. • F. Hoffmann-La Roche Ltd. • Allergan plc. • Bausch Health Companies Inc. • Regeneron Pharmaceuticals Inc. • Neurotech Pharmaceuticals Inc. • Ophthotech Corporation • Novartis AG • Pfizer Inc. • GlaxoSmithKline plc. • Bayer AG • Acucela Inc. • Rxi Pharmaceuticals, Inc. • Santen Pharmaceuticals Co • StemCells Inc. • Amgen Inc.,
Global Age Related Macular Degeneration (AMD) Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Age Related Macular Degeneration (AMD) Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast 6.1. Global Age Related Macular Degeneration (AMD) Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 7.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Type 7.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by Type 7.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Type 8. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by Drug 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 8.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Drug 8.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by Drug 8.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Drug 9. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by Stages 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 9.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Stages 9.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by Stages 9.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Stages 10. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by Age Group 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 10.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Age Group 10.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by Age Group 10.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Age Group 11. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by Route of Administration 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 11.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Route of Administration 11.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by Route of Administration 11.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Route of Administration 12. Global Age Related Macular Degeneration (AMD) Market Analysis and Forecast, by End User 12.1. Introduction and Definition 12.2. Key Findings 12.3. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 12.4. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by End User 12.5. Global Age Related Macular Degeneration (AMD) Market Analysis, by End User 12.6. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by End User 13. Global Age Related Macular Degeneration (AMD) Market Analysis, by Region 13.1. Global Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Region 13.2. Global Age Related Macular Degeneration (AMD) Market Size (US$ Bn) Forecast, by Region 13.3. Global Age Related Macular Degeneration (AMD) Market Attractiveness Analysis, by Region 14. North America Age Related Macular Degeneration (AMD) Market Analysis 14.1. Key Findings 14.2. North America Age Related Macular Degeneration (AMD) Market Overview 14.3. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 14.4. North America Age Related Macular Degeneration (AMD) Market Forecast, by Type 14.4.1. Dry Age-related Macular Degeneration (DAMD) 14.4.2. Wet Age-related Macular Degeneration (WAMD) 14.5. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 14.6. North America Age Related Macular Degeneration (AMD) Market Forecast, by Drug 14.6.1. Lucentis 14.6.2. Eylea 14.6.3. Avastin 14.6.4. Others 14.7. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 14.8. North America Age Related Macular Degeneration (AMD) Market Forecast, by Stages 14.8.1. Intermediate Stage Age Related Macular Degeneration 14.8.2. Early-Stage Age Related Macular Degeneration 14.8.3. Late Stage Age Related Macular Degeneration 14.9. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 14.10. North America Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 14.10.1. Above 75 Year 14.10.2. Above 60 Year 14.10.3. Above 40 Year 14.11. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 14.12. North America Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 14.12.1. Intravenous 14.12.2. Intravitreal 14.13. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 14.14. North America Age Related Macular Degeneration (AMD) Market Forecast, by End User 14.14.1. Hospitals & Clinics 14.14.2. Dignostic Centers 14.14.3. Academic Research Institutes 14.15. North America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Country 14.16. North America Age Related Macular Degeneration (AMD) Market Forecast, by Country 14.16.1. U.S. 14.16.2. Canada 14.17. North America Age Related Macular Degeneration (AMD) Market Analysis, by Country 14.18. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by Type 14.18.1. Dry Age-related Macular Degeneration (DAMD) 14.18.2. Wet Age-related Macular Degeneration (WAMD) 14.19. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by Drug 14.19.1. Lucentis 14.19.2. Eylea 14.19.3. Avastin 14.19.4. Others 14.20. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by Stages 14.20.1. Intermediate Stage Age Related Macular Degeneration 14.20.2. Early-Stage Age Related Macular Degeneration 14.20.3. Late Stage Age Related Macular Degeneration 14.21. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 14.21.1. Above 75 Year 14.21.2. Above 60 Year 14.21.3. Above 40 Year 14.22. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 14.22.1. Intravenous 14.22.2. Intravitreal 14.23. U.S. Age Related Macular Degeneration (AMD) Market Forecast, by End User 14.23.1. Hospitals & Clinics 14.23.2. Dignostic Centers 14.23.3. Academic Research Institutes 14.24. Canada Age Related Macular Degeneration (AMD) Market Forecast, by Type 14.24.1. Dry Age-related Macular Degeneration (DAMD) 14.24.2. Wet Age-related Macular Degeneration (WAMD) 14.25. Canada Age Related Macular Degeneration (AMD) Market Forecast, by Drug 14.25.1. Lucentis 14.25.2. Eylea 14.25.3. Avastin 14.25.4. Others 14.26. Canada Age Related Macular Degeneration (AMD) Market Forecast, by Stages 14.26.1. Intermediate Stage Age Related Macular Degeneration 14.26.2. Early-Stage Age Related Macular Degeneration 14.26.3. Late Stage Age Related Macular Degeneration 14.27. Canada Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 14.27.1. Above 75 Year 14.27.2. Above 60 Year 14.27.3. Above 40 Year 14.28. Canada Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 14.28.1. Intravenous 14.28.2. Intravitreal 14.29. Canada Age Related Macular Degeneration (AMD) Market Forecast, by End User 14.29.1. Hospitals & Clinics 14.29.2. Dignostic Centers 14.29.3. Academic Research Institutes 14.30. North America Age Related Macular Degeneration (AMD) Market Attractiveness Analysis 14.30.1. By Type 14.30.2. By Drug 14.30.3. By Stages 14.30.4. By Age Group 14.30.5. By Route of Administration 14.30.6. By End User 14.31. PEST Analysis 15. Europe Age Related Macular Degeneration (AMD) Market Analysis 15.1. Key Findings 15.2. Europe Age Related Macular Degeneration (AMD) Market Overview 15.3. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 15.4. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.4.1. Dry Age-related Macular Degeneration (DAMD) 15.4.2. Wet Age-related Macular Degeneration (WAMD) 15.5. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 15.6. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.6.1. Lucentis 15.6.2. Eylea 15.6.3. Avastin 15.6.4. Others 15.7. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 15.8. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.8.1. Intermediate Stage Age Related Macular Degeneration 15.8.2. Early-Stage Age Related Macular Degeneration 15.8.3. Late Stage Age Related Macular Degeneration 15.9. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 15.10. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.10.1. Above 75 Year 15.10.2. Above 60 Year 15.10.3. Above 40 Year 15.11. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 15.12. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.12.1. Intravenous 15.12.2. Intravitreal 15.13. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 15.14. Europe Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.14.1. Hospitals & Clinics 15.14.2. Dignostic Centers 15.14.3. Academic Research Institutes 15.15. Europe Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Country 15.16. Europe Age Related Macular Degeneration (AMD) Market Forecast, by Country 15.16.1. Germany 15.16.2. U.K. 15.16.3. France 15.16.4. Italy 15.16.5. Spain 15.16.6. Rest of Europe 15.17. Europe Age Related Macular Degeneration (AMD) Market Analysis, by Country 15.18. Germany Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.18.1. Dry Age-related Macular Degeneration (DAMD) 15.18.2. Wet Age-related Macular Degeneration (WAMD) 15.19. Germany Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.19.1. Lucentis 15.19.2. Eylea 15.19.3. Avastin 15.19.4. Others 15.20. Germany Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.20.1. Intermediate Stage Age Related Macular Degeneration 15.20.2. Early-Stage Age Related Macular Degeneration 15.20.3. Late Stage Age Related Macular Degeneration 15.21. Germany Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.21.1. Above 75 Year 15.21.2. Above 60 Year 15.21.3. Above 40 Year 15.22. Germany Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.22.1. Intravenous 15.22.2. Intravitreal 15.23. Germany Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.23.1. Hospitals & Clinics 15.23.2. Dignostic Centers 15.23.3. Academic Research Institutes 15.24. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.24.1. Dry Age-related Macular Degeneration (DAMD) 15.24.2. Wet Age-related Macular Degeneration (WAMD) 15.25. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.25.1. Lucentis 15.25.2. Eylea 15.25.3. Avastin 15.25.4. Others 15.26. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.26.1. Intermediate Stage Age Related Macular Degeneration 15.26.2. Early-Stage Age Related Macular Degeneration 15.26.3. Late Stage Age Related Macular Degeneration 15.27. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.27.1. Above 75 Year 15.27.2. Above 60 Year 15.27.3. Above 40 Year 15.28. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.28.1. Intravenous 15.28.2. Intravitreal 15.29. U.K. Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.29.1. Hospitals & Clinics 15.29.2. Dignostic Centers 15.29.3. Academic Research Institutes 15.30. France Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.30.1. Dry Age-related Macular Degeneration (DAMD) 15.30.2. Wet Age-related Macular Degeneration (WAMD) 15.31. France Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.31.1. Lucentis 15.31.2. Eylea 15.31.3. Avastin 15.31.4. Others 15.32. France Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.32.1. Intermediate Stage Age Related Macular Degeneration 15.32.2. Early-Stage Age Related Macular Degeneration 15.32.3. Late Stage Age Related Macular Degeneration 15.33. France Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.33.1. Above 75 Year 15.33.2. Above 60 Year 15.33.3. Above 40 Year 15.34. France Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.34.1. Intravenous 15.34.2. Aftermarket Services 15.35. France Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.35.1. Hospitals & Clinics 15.35.2. Dignostic Centers 15.35.3. Academic Research Institutes 15.36. Italy Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.36.1. Dry Age-related Macular Degeneration (DAMD) 15.36.2. Wet Age-related Macular Degeneration (WAMD) 15.37. Italy Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.37.1. Lucentis 15.37.2. Eylea 15.37.3. Avastin 15.37.4. Others 15.38. Italy Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.38.1. Intermediate Stage Age Related Macular Degeneration 15.38.2. Early-Stage Age Related Macular Degeneration 15.38.3. Late Stage Age Related Macular Degeneration 15.39. Italy Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.39.1. Above 75 Year 15.39.2. Above 60 Year 15.39.3. Above 40 Year 15.40. Italy Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.40.1. Intravenous 15.40.2. Intravitreal 15.41. Italy Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.41.1. Hospitals & Clinics 15.41.2. Dignostic Centers 15.41.3. Academic Research Institutes 15.42. Spain Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.42.1. Dry Age-related Macular Degeneration (DAMD) 15.42.2. Wet Age-related Macular Degeneration (WAMD) 15.43. Spain Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.43.1. Lucentis 15.43.2. Eylea 15.43.3. Avastin 15.43.4. Others 15.44. Spain Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.44.1. Intermediate Stage Age Related Macular Degeneration 15.44.2. Early-Stage Age Related Macular Degeneration 15.44.3. Late Stage Age Related Macular Degeneration 15.45. Spain Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.45.1. Above 75 Year 15.45.2. Above 60 Year 15.45.3. Above 40 Year 15.46. Spain Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.46.1. Intravenous 15.46.2. Intravitreal 15.47. Spain Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.47.1. Hospitals & Clinics 15.47.2. Dignostic Centers 15.47.3. Academic Research Institutes 15.48. Rest of Europe Age Related Macular Degeneration (AMD) Market Forecast, by Type 15.48.1. Dry Age-related Macular Degeneration (DAMD) 15.48.2. Wet Age-related Macular Degeneration (WAMD) 15.49. Rest of Europe Age Related Macular Degeneration (AMD) Market Forecast, by Drug 15.49.1. Lucentis 15.49.2. Eylea 15.49.3. Avastin 15.49.4. Others 15.50. Rest of Europe Age Related Macular Degeneration (AMD) Market Forecast, by Stages 15.50.1. Intermediate Stage Age Related Macular Degeneration 15.50.2. Early-Stage Age Related Macular Degeneration 15.50.3. Late Stage Age Related Macular Degeneration 15.51. Rest Of Europe Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 15.51.1. Above 75 Year 15.51.2. Above 60 Year 15.51.3. Above 40 Year 15.52. Rest Of Europe Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 15.52.1. Intravenous 15.52.2. Intravitreal 15.53. Rest Of Europe Age Related Macular Degeneration (AMD) Market Forecast, by End User 15.53.1. Hospitals & Clinics 15.53.2. Dignostic Centers 15.53.3. Academic Research Institutes 15.54. Europe Age Related Macular Degeneration (AMD) Market Attractiveness Analysis 15.54.1. By Type 15.54.2. By Drug 15.54.3. By Stages 15.54.4. By Age Group 15.54.5. By Route of Administration 15.54.6. By End User 15.55. PEST Analysis 16. Asia Pacific Age Related Macular Degeneration (AMD) Market Analysis 16.1. Key Findings 16.2. Asia Pacific Age Related Macular Degeneration (AMD) Market Overview 16.3. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 16.4. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.4.1. Dry Age-related Macular Degeneration (DAMD) 16.4.2. Wet Age-related Macular Degeneration (WAMD) 16.5. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 16.6. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.6.1. Lucentis 16.6.2. Eylea 16.6.3. Avastin 16.6.4. Others 16.7. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 16.8. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.8.1. Intermediate Stage Age Related Macular Degeneration 16.8.2. Early-Stage Age Related Macular Degeneration 16.8.3. Late Stage Age Related Macular Degeneration 16.9. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 16.10. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.10.1. Above 75 Year 16.10.2. Above 60 Year 16.10.3. Above 40 Year 16.11. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 16.12. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.12.1. Intravenous 16.12.2. Intravitreal 16.13. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 16.14. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.14.1. Hospitals & Clinics 16.14.2. Dignostic Centers 16.14.3. Academic Research Institutes 16.15. Asia Pacific Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Country 16.16. Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Country 16.16.1. China 16.16.2. India 16.16.3. Japan 16.16.4. ASEAN 16.16.5. Rest of Asia Pacific 16.17. Asia Pacific Age Related Macular Degeneration (AMD) Market Analysis, by Country 16.18. China Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.18.1. Dry Age-related Macular Degeneration (DAMD) 16.18.2. Wet Age-related Macular Degeneration (WAMD) 16.19. China Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.19.1. Lucentis 16.19.2. Eylea 16.19.3. Avastin 16.19.4. Others 16.20. China Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.20.1. Intermediate Stage Age Related Macular Degeneration 16.20.2. Early-Stage Age Related Macular Degeneration 16.20.3. Late Stage Age Related Macular Degeneration 16.21. China Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.21.1. Above 75 Year 16.21.2. Above 60 Year 16.21.3. Above 40 Year 16.22. China Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.22.1. Intravenous 16.22.2. Intravitreal 16.23. China Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.23.1. Hospitals & Clinics 16.23.2. Dignostic Centers 16.23.3. Academic Research Institutes 16.24. India Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.24.1. Dry Age-related Macular Degeneration (DAMD) 16.24.2. Wet Age-related Macular Degeneration (WAMD) 16.25. India Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.25.1. Lucentis 16.25.2. Eylea 16.25.3. Avastin 16.25.4. Others 16.26. India Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.26.1. Intermediate Stage Age Related Macular Degeneration 16.26.2. Early-Stage Age Related Macular Degeneration 16.26.3. Late Stage Age Related Macular Degeneration 16.27. India Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.27.1. Above 75 Year 16.27.2. Above 60 Year 16.27.3. Above 40 Year 16.28. India Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.28.1. Intravenous 16.28.2. Intravitreal 16.29. India Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.29.1. Hospitals & Clinics 16.29.2. Dignostic Centers 16.29.3. Academic Research Institutes 16.30. Japan Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.30.1. Dry Age-related Macular Degeneration (DAMD) 16.30.2. Wet Age-related Macular Degeneration (WAMD) 16.31. Japan Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.31.1. Lucentis 16.31.2. Eylea 16.31.3. Avastin 16.31.4. Others 16.32. Japan Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.32.1. Intermediate Stage Age Related Macular Degeneration 16.32.2. Early-Stage Age Related Macular Degeneration 16.32.3. Late Stage Age Related Macular Degeneration 16.33. Japan Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.33.1. Above 75 Year 16.33.2. Above 60 Year 16.33.3. Above 40 Year 16.34. Japan Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.34.1. Intravenous 16.34.2. Intravitreal 16.35. Japan Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.35.1. Hospitals & Clinics 16.35.2. Dignostic Centers 16.35.3. Academic Research Institutes 16.36. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.36.1. Dry Age-related Macular Degeneration (DAMD) 16.36.2. Wet Age-related Macular Degeneration (WAMD) 16.37. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.37.1. Lucentis 16.37.2. Eylea 16.37.3. Avastin 16.37.4. Others 16.38. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.38.1. Intermediate Stage Age Related Macular Degeneration 16.38.2. Early-Stage Age Related Macular Degeneration 16.38.3. Late Stage Age Related Macular Degeneration 16.39. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.39.1. Above 75 Year 16.39.2. Above 60 Year 16.39.3. Above 40 Year 16.40. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.40.1. Intravenous 16.40.2. Intravitreal 16.41. ASEAN Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.41.1. Hospitals & Clinics 16.41.2. Dignostic Centers 16.41.3. Academic Research Institutes 16.42. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Type 16.42.1. Dry Age-related Macular Degeneration (DAMD) 16.42.2. Wet Age-related Macular Degeneration (WAMD) 16.43. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Drug 16.43.1. Lucentis 16.43.2. Eylea 16.43.3. Avastin 16.43.4. Others 16.44. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Stages 16.44.1. Intermediate Stage Age Related Macular Degeneration 16.44.2. Early-Stage Age Related Macular Degeneration 16.44.3. Late Stage Age Related Macular Degeneration 16.45. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 16.45.1. Above 75 Year 16.45.2. Above 60 Year 16.45.3. Above 40 Year 16.46. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 16.46.1. Intravenous 16.46.2. Intravitreal 16.47. Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market Forecast, by End User 16.47.1. Hospitals & Clinics 16.47.2. Dignostic Centers 16.47.3. Academic Research Institutes 16.48. Asia Pacific Age Related Macular Degeneration (AMD) Market Attractiveness Analysis 16.48.1. By Type 16.48.2. By Drug 16.48.3. By Stages 16.48.4. By Age Group 16.48.5. By Route of Administration 16.48.6. By End User 16.49. PEST Analysis 17. Middle East & Africa Age Related Macular Degeneration (AMD) Market Analysis 17.1. Key Findings 17.2. Middle East & Africa Age Related Macular Degeneration (AMD) Market Overview 17.3. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 17.4. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Type 17.4.1. Dry Age-related Macular Degeneration (DAMD) 17.4.2. Wet Age-related Macular Degeneration (WAMD) 17.5. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 17.6. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Drug 17.6.1. Lucentis 17.6.2. Eylea 17.6.3. Avastin 17.6.4. Others 17.7. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 17.8. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Stages 17.8.1. Intermediate Stage Age Related Macular Degeneration 17.8.2. Early-Stage Age Related Macular Degeneration 17.8.3. Late Stage Age Related Macular Degeneration 17.9. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 17.10. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 17.10.1. Above 75 Year 17.10.2. Above 60 Year 17.10.3. Above 40 Year 17.11. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 17.12. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 17.12.1. Intravenous 17.12.2. Intravitreal 17.13. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 17.14. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by End User 17.14.1. Hospitals & Clinics 17.14.2. Dignostic Centers 17.14.3. Academic Research Institutes 17.15. Middle East & Africa Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Country 17.16. Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Country 17.16.1. GCC 17.16.2. South Africa 17.16.3. Rest of Middle East & Africa 17.17. Middle East & Africa Age Related Macular Degeneration (AMD) Market Analysis, by Country 17.18. GCC Age Related Macular Degeneration (AMD) Market Forecast, by Type 17.18.1. Dry Age-related Macular Degeneration (DAMD) 17.18.2. Wet Age-related Macular Degeneration (WAMD) 17.19. GCC Age Related Macular Degeneration (AMD) Market Forecast, by Drug 17.19.1. Lucentis 17.19.2. Eylea 17.19.3. Avastin 17.19.4. Others 17.20. GCC Age Related Macular Degeneration (AMD) Market Forecast, by Stages 17.20.1. Intermediate Stage Age Related Macular Degeneration 17.20.2. Early-Stage Age Related Macular Degeneration 17.20.3. Late Stage Age Related Macular Degeneration 17.21. GCC Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 17.21.1. Above 75 Year 17.21.2. Above 60 Year 17.21.3. Above 40 Year 17.22. GCC Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 17.22.1. Intravenous 17.22.2. Intravitreal 17.23. GCC Age Related Macular Degeneration (AMD) Market Forecast, by End User 17.23.1. Hospitals & Clinics 17.23.2. Dignostic Centers 17.23.3. Academic Research Institutes 17.24. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by Type 17.24.1. Dry Age-related Macular Degeneration (DAMD) 17.24.2. Wet Age-related Macular Degeneration (WAMD) 17.25. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by Drug 17.25.1. Lucentis 17.25.2. Eylea 17.25.3. Avastin 17.25.4. Others 17.26. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by Stages 17.26.1. Intermediate Stage Age Related Macular Degeneration 17.26.2. Early-Stage Age Related Macular Degeneration 17.26.3. Late Stage Age Related Macular Degeneration 17.27. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 17.27.1. Above 75 Year 17.27.2. Above 60 Year 17.27.3. Above 40 Year 17.28. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 17.28.1. Intravenous 17.28.2. Intravitreal 17.29. South Africa Age Related Macular Degeneration (AMD) Market Forecast, by End User 17.29.1. Hospitals & Clinics 17.29.2. Dignostic Centers 17.29.3. Academic Research Institutes 17.30. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Type 17.30.1. Dry Age-related Macular Degeneration (DAMD) 17.30.2. Wet Age-related Macular Degeneration (WAMD) 17.31. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Drug 17.31.1. Lucentis 17.31.2. Eylea 17.31.3. Avastin 17.31.4. Others 17.32. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Stages 17.32.1. Intermediate Stage Age Related Macular Degeneration 17.32.2. Early-Stage Age Related Macular Degeneration 17.32.3. Late Stage Age Related Macular Degeneration 17.33. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 17.33.1. Above 75 Year 17.33.2. Above 60 Year 17.33.3. Above 40 Year 17.34. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 17.34.1. Intravenous 17.34.2. Intravitreal 17.35. Rest of Middle East & Africa Age Related Macular Degeneration (AMD) Market Forecast, by End User 17.35.1. Hospitals & Clinics 17.35.2. Dignostic Centers 17.35.3. Academic Research Institutes 17.36. Middle East & Africa Age Related Macular Degeneration (AMD) Market Attractiveness Analysis 17.36.1. By Type 17.36.2. By Drug 17.36.3. By Stages 17.36.4. By Age Group 17.36.5. By Route of Administration 17.36.6. By End User 17.37. PEST Analysis 18. South America Age Related Macular Degeneration (AMD) Market Analysis 18.1. Key Findings 18.2. South America Age Related Macular Degeneration (AMD) Market Overview 18.3. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Type 18.4. South America Age Related Macular Degeneration (AMD) Market Forecast, by Type 18.4.1. Dry Age-related Macular Degeneration (DAMD) 18.4.2. Wet Age-related Macular Degeneration (WAMD) 18.5. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Drug 18.6. South America Age Related Macular Degeneration (AMD) Market Forecast, by Drug 18.6.1. Lucentis 18.6.2. Eylea 18.6.3. Avastin 18.6.4. Others 18.7. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Stages 18.8. South America Age Related Macular Degeneration (AMD) Market Forecast, by Stages 18.8.1. Intermediate Stage Age Related Macular Degeneration 18.8.2. Early-Stage Age Related Macular Degeneration 18.8.3. Late Stage Age Related Macular Degeneration 18.9. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Age Group 18.10. South America Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 18.10.1. Above 75 Year 18.10.2. Above 60 Year 18.10.3. Above 40 Year 18.11. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Route of Administration 18.12. South America Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 18.12.1. Intravenous 18.12.2. Intravitreal 18.13. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by End User 18.14. South America Age Related Macular Degeneration (AMD) Market Forecast, by End User 18.14.1. Hospitals & Clinics 18.14.2. Dignostic Centers 18.14.3. Academic Research Institutes 18.15. South America Age Related Macular Degeneration (AMD) Market Value Share Analysis, by Country 18.16. South America Age Related Macular Degeneration (AMD) Market Forecast, by Country 18.16.1. Brazil 18.16.2. Mexico 18.16.3. Rest of South America 18.17. South America Age Related Macular Degeneration (AMD) Market Analysis, by Country 18.18. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by Type 18.18.1. Dry Age-related Macular Degeneration (DAMD) 18.18.2. Wet Age-related Macular Degeneration (WAMD) 18.19. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by Drug 18.19.1. Lucentis 18.19.2. Eylea 18.19.3. Avastin 18.19.4. Others 18.20. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by Stages 18.20.1. Intermediate Stage Age Related Macular Degeneration 18.20.2. Early-Stage Age Related Macular Degeneration 18.20.3. Late Stage Age Related Macular Degeneration 18.21. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 18.21.1. Above 75 Year 18.21.2. Above 60 Year 18.21.3. Above 40 Year 18.22. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 18.22.1. Intravenous 18.22.2. Intravitreal 18.23. Brazil Age Related Macular Degeneration (AMD) Market Forecast, by End User 18.23.1. Hospitals & Clinics 18.23.2. Dignostic Centers 18.23.3. Academic Research Institutes 18.24. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by Type 18.24.1. Dry Age-related Macular Degeneration (DAMD) 18.24.2. Wet Age-related Macular Degeneration (WAMD) 18.25. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by Drug 18.25.1. Lucentis 18.25.2. Eylea 18.25.3. Avastin 18.25.4. Others 18.26. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by Stages 18.26.1. Intermediate Stage Age Related Macular Degeneration 18.26.2. Early-Stage Age Related Macular Degeneration 18.26.3. Late Stage Age Related Macular Degeneration 18.27. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 18.27.1. Above 75 Year 18.27.2. Above 60 Year 18.27.3. Above 40 Year 18.28. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 18.28.1. Intravenous 18.28.2. Intravitreal 18.29. Mexico Age Related Macular Degeneration (AMD) Market Forecast, by End User 18.29.1. Hospitals & Clinics 18.29.2. Dignostic Centers 18.29.3. Academic Research Institutes 18.30. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by Type 18.30.1. Dry Age-related Macular Degeneration (DAMD) 18.30.2. Wet Age-related Macular Degeneration (WAMD) 18.31. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by Drug 18.31.1. Lucentis 18.31.2. Eylea 18.31.3. Avastin 18.31.4. Others 18.32. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by Stages 18.32.1. Intermediate Stage Age Related Macular Degeneration 18.32.2. Early-Stage Age Related Macular Degeneration 18.32.3. Late Stage Age Related Macular Degeneration 18.33. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by Age Group 18.33.1. Above 75 Year 18.33.2. Above 60 Year 18.33.3. Above 40 Year 18.34. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by Route of Administration 18.34.1. Intravenous 18.34.2. Intravitreal 18.35. Rest of South America Age Related Macular Degeneration (AMD) Market Forecast, by End User 18.35.1. Hospitals & Clinics 18.35.2. Dignostic Centers 18.35.3. Academic Research Institutes 18.36. South America Age Related Macular Degeneration (AMD) Market Attractiveness Analysis 18.36.1. By Type 18.36.2. By Drug 18.36.3. By Stages 18.36.4. By Age Group 18.36.5. By Route of Administration 18.36.6. By End User 18.37. PEST Analysis 19. Company Profiles 19.1. Market Share Analysis, by Company 19.2. Competition Matrix 19.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 19.2.2. New Product Launches and Product Enhancements 19.2.3. Market Consolidation 19.2.3.1. M&A by Regions, Investment and Applications 19.2.3.2. M&A Key Players, Forward Integration and Backward Integration 19.3. Company Profiles: Key Players 19.3.1. Kubota Pharmaceutical Holdings Co. Ltd 19.3.1.1. Company Overview 19.3.1.2. Financial Overview 19.3.1.3. End User Portfolio 19.3.1.4. Business Strategy 19.3.1.5. Recent Developments 19.3.1.6. Development Footprint 19.3.2. Alimera Sciences Inc. 19.3.3. Adverum Biotechnologies Inc. 19.3.4. Gilead Sciences Inc. 19.3.5. Apellis Pharmeceuticals Inc. 19.3.6. F. Hoffmann-La Roche Ltd. 19.3.7. Allergan plc. 19.3.8. Bausch Health Companies Inc. 19.3.9. Regeneron Pharmaceuticals Inc. 19.3.10. Neurotech Pharmaceuticals Inc. 19.3.11. Ophthotech Corporation 19.3.12. Novartis AG 19.3.13. Pfizer Inc. 19.3.14. GlaxoSmithKline plc. 19.3.15. Bayer AG 19.3.16. Acucela Inc. 19.3.17. Rxi Pharmaceuticals, Inc. 19.3.18. Santen Pharmaceuticals Co 19.3.19. StemCells Inc. 19.3.20. Amgen Inc., 20. Primary Key Insights

About This Report

Report ID36109
Category Healthcare
Published DateNov 2019
Updated DateDec 2020
Contact Us